CD274 and metastatic melanoma: Monoclonal antibodies against PD-1 and PD-L1, pembrolizumab (keytruda)/nivolumab (opdivo) and atezolizumab (tecentriq), respectively, were approved for the treatment of unresectable/metastatic melanoma.